Suppr超能文献

放射性碘治疗后甲状腺摄取的随访:治疗期剂量学的稳健性如何?

Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?

机构信息

Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Köln, Germany.

出版信息

Z Med Phys. 2011 Dec;21(4):258-65. doi: 10.1016/j.zemedi.2011.04.006. Epub 2011 Jun 29.

Abstract

Radioiodine therapy (RIT) for benign thyroid diseases in Germany requires the patient to stay in a nuclear medicine therapy ward for at least 48 hours and the dose to the thyroid to be computed from activity measurements performed during that stay. A major part of the total dose will be delivered after the patient's discharge from the hospital and thus has to be predicted through extrapolation with the effective half-life measured peri-therapeutically. We performed repeated thyroid uptake measurements on patients up to five months post therapy to investigate post-therapeutic changes in their effective half-lives and examine the dosimetric consequences. 12 patients (4 m, 8 f; age 36 - 76 y; 4 Graves' disease, 4 toxic adenoma, 3 toxic goitre, 1 non-toxic goitre) underwent late uptake measurements (1 - 7 meas., 13 - 154 d post administration, median 54 d, performed with thyroid probe resp. whole body counter at lower activities). Doses calculated from late measurements were compared to those predicted at discharge; half-lives calculated from the late measurement closest to the median delay (54 d) were compared to those determined at time of discharge. A cross-calibration between activity calibrator, thyroid probe, and whole body counter over an activity range from 52 MBq down to 45 Bq revealed linearity to within 6%, which was considered sufficient. In 9 out of 12 patients the achieved dose was within the range predicted at discharge. Averaged deviation between achieved and predicted dose was 3.1±2.2% (median 2.5%, range 0.7% - 7.2%). Averaged deviation between post- and peri-therapeutic half-lives was 5.1±3.9% (median 3.5%, range 1.3% - 12.5%). For n=5 patients discharged after 3 days, averaged deviations were greater (dose 4.0%, half-life 5.6%) than for those patients (n=7) who stayed in the hospital for a minimum of 4 days (dose 2.5%, half-life 4.8%). Excretion of iodine from the thyroid remains practically unchanged for at least two months after RIT. The dosimetric procedure implemented in our institution warrants a robust prediction of the post-therapeutic half-life and thus the actual achieved dose.

摘要

放射性碘治疗(RIT)用于德国的良性甲状腺疾病需要患者在核医学治疗病房至少停留 48 小时,并根据在此期间进行的活动测量来计算甲状腺的剂量。大部分剂量将在患者出院后给予,因此必须通过在治疗期间测量的有效半衰期的外推来预测。我们对接受治疗后 5 个月的患者进行了重复的甲状腺摄取测量,以研究治疗后有效半衰期的变化,并检查剂量学后果。12 名患者(4 名男性,8 名女性;年龄 36-76 岁;4 名格雷夫斯病,4 名毒性腺瘤,3 名毒性甲状腺肿,1 名非毒性甲状腺肿)接受了晚期摄取测量(1-7 次测量,接受放射性碘治疗后 13-154 天,中位数 54 天,使用甲状腺探头或全身计数器在较低活性下进行)。从晚期测量计算的剂量与出院时预测的剂量进行比较;从最接近中位数延迟(54 天)的晚期测量计算的半衰期与出院时确定的半衰期进行比较。在 52 MBq 至 45 Bq 的活性范围内,对活性校准器、甲状腺探头和全身计数器进行了交叉校准,结果表明线性度在 6%以内,这被认为是足够的。在 12 名患者中的 9 名中,实际剂量在出院时预测的剂量范围内。实际剂量与预测剂量的平均偏差为 3.1±2.2%(中位数 2.5%,范围 0.7%-7.2%)。治疗后和治疗期间半衰期的平均偏差为 5.1±3.9%(中位数 3.5%,范围 1.3%-12.5%)。对于在 3 天后出院的 n=5 名患者,平均偏差较大(剂量 4.0%,半衰期 5.6%),而对于在医院至少停留 4 天的 n=7 名患者(剂量 2.5%,半衰期 4.8%)。放射性碘治疗后至少两个月,甲状腺中碘的排泄基本保持不变。我们机构实施的剂量学程序可以可靠地预测治疗后半衰期,从而预测实际的治疗剂量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验